BROOMFIELD, Colorado, February 17 /PRNewswire/ --
Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today it is a SILVER level sponsor of the 2009 International Conference on Alzheimer's Disease (ICAD). The annual conference, put on by the Alzheimer's Association, is the world's leading forum on dementia research. ICAD 2009 will take place July 11-16 in Vienna, Austria.
Alzheimer's is a progressive and fatal disease that significantly impacts millions of patients, their families and caregivers, said Steve Orndorff, Ph.D., Accera's founder and CEO. As a company focused on CNS disorders, Accera is committed to improving the care and quality of life of Alzheimer's patients who are in need of innovative, safe, new therapeutic options. By supporting ICAD we are joining the Alzheimer's Association in their quest to advance research, care and support for AD.
In the U.S., 5.2 million people are living with AD and it has become the sixth leading cause of death. There is currently no cure for AD and there is a tremendous need for new and innovative therapies.
ICAD 2009 is expected to draw approximately 5,000 researchers, clinicians and neurologists from around the world to engage in a multidisciplinary exchange of ideas. The international sharing of research looks to advance prevention methods, treatments and a cure for AD.
About ICAD
The Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) is the largest gathering of international leaders in Alzheimer research and care. At ICAD, researchers from around the world share groundbreaking information and resources on the cause, diagnosis, treatment and prevention of Alzheimer's and related disorders. As a part of the Association's research program, ICAD serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community.
About the Alzheimer's Association
The Alzheimer's Association, the nonprofit world leader in Alzheimer's research and support, is the first and largest U.S. voluntary health organization dedicated to finding prevention methods, treatments and an eventual cure for Alzheimer's. For more than 25 years, the donor-supported Alzheimer's Association has provided reliable information and care consultation; created supportive services for families; increased funding for dementia research; and influenced public policy changes. For more information, call +1-800-272-3900 or visit www.alz.org.
About Accera, Inc.
Accera, Inc., a privately held biotechnology company, discovers and develops therapeutic breakthroughs in central nervous systems disorders. Accera's novel approaches positively impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, Accera is developing products that address metabolic deficiencies associated with certain neurodegenerative diseases by providing an alternative energy source for the brain. For more information, visit www.accerapharma.com.
Contacts
Media: Greg Tiberend Richard Lewis Communications, Inc +1-212-827-0020 gtiberend@rlcinc.com
Greg Tiberend of Richard Lewis Communications, Inc, +1-212-827-0020, gtiberend@rlcinc.com, for Accera, Inc.
Comments